Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 96 entries
Sorted by: Best Match Show Resources per page
Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease.

Cellular and molecular gastroenterology and hepatology

Li X, LeBlanc J, Elashoff D, McHardy I, Tong M, Roth B, Ippoliti A, Barron G, McGovern D, McDonald K, Newberry R, Graeber T, Horvath S, Goodglick L, Braun J.
PMID: 28174738
Cell Mol Gastroenterol Hepatol. 2016 May 17;2(5):567-583. doi: 10.1016/j.jcmgh.2016.05.003. eCollection 2016 Sep.

BACKGROUND & AIMS: Interactions between mucosal cell types, environmental stressors, and intestinal microbiota contribute to pathogenesis in inflammatory bowel disease (IBD). Here, we applied metaproteomics of the mucosal-luminal interface to study the disease-related biology of the human colonic mucosa.METHODS:...

Cite
Li X, LeBlanc J, Elashoff D, et al. Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol. 2016;2(5):567-583doi: 10.1016/j.jcmgh.2016.05.003.
Li, X., LeBlanc, J., Elashoff, D., McHardy, I., Tong, M., Roth, B., Ippoliti, A., Barron, G., McGovern, D., McDonald, K., Newberry, R., Graeber, T., Horvath, S., Goodglick, L., & Braun, J. (2016). Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease. Cellular and molecular gastroenterology and hepatology, 2(5), 567-583. https://doi.org/10.1016/j.jcmgh.2016.05.003
Li, Xiaoxiao, et al. "Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease." Cellular and molecular gastroenterology and hepatology vol. 2,5 (2016): 567-583. doi: https://doi.org/10.1016/j.jcmgh.2016.05.003
Li X, LeBlanc J, Elashoff D, McHardy I, Tong M, Roth B, Ippoliti A, Barron G, McGovern D, McDonald K, Newberry R, Graeber T, Horvath S, Goodglick L, Braun J. Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol. 2016 May 17;2(5):567-583. doi: 10.1016/j.jcmgh.2016.05.003. eCollection 2016 Sep. PMID: 28174738; PMCID: PMC5042708.
Copy Download .nbib Format: NLM
Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease.

Rheumatology (Sunnyvale, Calif.)

Volkmann ER, Tashkin DP, Li N, Furst DE, Clements PJ, Elashoff RM.
PMID: 28856069
Rheumatology (Sunnyvale). 2015 Jun;5(2). doi: 10.4172/2161-1149.1000154. Epub 2015 Jun 30.

OBJECTIVE: While systemic sclerosis-related interstitial lung disease (SSc-ILD) trials predominantly use forced vital capacity (FVC) as the primary outcome, combining individual outcomes may lead to a more comprehensive measure of treatment response and minimize the risk of type 1...

Cite
Volkmann ER, Tashkin DP, Li N, et al. Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. Rheumatology (Sunnyvale). 2015;5(2)doi: 10.4172/2161-1149.1000154.
Volkmann, E. R., Tashkin, D. P., Li, N., Furst, D. E., Clements, P. J., & Elashoff, R. M. (2015). Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. Rheumatology (Sunnyvale, Calif.), 5(2), . https://doi.org/10.4172/2161-1149.1000154
Volkmann, Elizabeth R, et al. "Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease." Rheumatology (Sunnyvale, Calif.) vol. 5,2 (2015). doi: https://doi.org/10.4172/2161-1149.1000154
Volkmann ER, Tashkin DP, Li N, Furst DE, Clements PJ, Elashoff RM. Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease. Rheumatology (Sunnyvale). 2015 Jun;5(2). doi: 10.4172/2161-1149.1000154. Epub 2015 Jun 30. PMID: 28856069; PMCID: PMC5573239.
Copy Download .nbib Format: NLM
Depression in Nonclassical Hypogonadism in Young Men.

Journal of the Endocrine Society

Korenman SG, Grotts JF, Bell DS, Elashoff DA.
PMID: 30430144
J Endocr Soc. 2018 Sep 21;2(11):1306-1313. doi: 10.1210/js.2018-00137. eCollection 2018 Nov 01.

The specific objective of this study was to test the clinically derived hypothesis associating a high prevalence of depression in young men with nonclassical hypogonadism. We studied the entire population of men aged 18 to 40 years who had...

Cite
Korenman SG, Grotts JF, Bell DS, et al. Depression in Nonclassical Hypogonadism in Young Men. J Endocr Soc. 2018;2(11):1306-1313doi: 10.1210/js.2018-00137.
Korenman, S. G., Grotts, J. F., Bell, D. S., & Elashoff, D. A. (2018). Depression in Nonclassical Hypogonadism in Young Men. Journal of the Endocrine Society, 2(11), 1306-1313. https://doi.org/10.1210/js.2018-00137
Korenman, Stanley G, et al. "Depression in Nonclassical Hypogonadism in Young Men." Journal of the Endocrine Society vol. 2,11 (2018): 1306-1313. doi: https://doi.org/10.1210/js.2018-00137
Korenman SG, Grotts JF, Bell DS, Elashoff DA. Depression in Nonclassical Hypogonadism in Young Men. J Endocr Soc. 2018 Sep 21;2(11):1306-1313. doi: 10.1210/js.2018-00137. eCollection 2018 Nov 01. PMID: 30430144; PMCID: PMC6223247.
Copy Download .nbib Format: NLM
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors.

JAMA network open

Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C.
PMID: 34459906
JAMA Netw Open. 2021 Aug 02;4(8):e2122998. doi: 10.1001/jamanetworkopen.2021.22998.

IMPORTANCE: Immune checkpoint inhibitors can produce distinct toxic effects that require prompt recognition and timely management.OBJECTIVE: To develop a technology-enabled, dynamically adaptive protocol that can provide the accurate information needed to inform specific remedies for immune toxic effects in...

Cite
Msaouel P, Oromendia C, Siefker-Radtke AO, et al. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021;4(8):e2122998doi: 10.1001/jamanetworkopen.2021.22998.
Msaouel, P., Oromendia, C., Siefker-Radtke, A. O., Tannir, N. M., Subudhi, S. K., Gao, J., Wang, Y., Siddiqui, B. A., Shah, A. Y., Aparicio, A. M., Campbell, M. T., Zurita, A. J., Shaw, L. K., Lopez, L. P., McCord, H., Chakraborty, S. N., Perales, J., Lu, C., Van Alstine, M. L., Elashoff, M., & Logothetis, C. (2021). Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA network open, 4(8), e2122998. https://doi.org/10.1001/jamanetworkopen.2021.22998
Msaouel, Pavlos, et al. "Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors." JAMA network open vol. 4,8 (2021): e2122998. doi: https://doi.org/10.1001/jamanetworkopen.2021.22998
Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 Aug 02;4(8):e2122998. doi: 10.1001/jamanetworkopen.2021.22998. PMID: 34459906; PMCID: PMC8406081.
Copy Download .nbib Format: NLM
Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis.

Digestive diseases and sciences

Dong TS, Jacobs JP, Agopian V, Pisegna JR, Ayoub W, Durazo F, Enayati P, Sundaram V, Benhammou JN, Noureddin M, Choi G, Lagishetty V, Fiehn O, Goodman MT, Elashoff D, Hussain SK.
PMID: 34799768
Dig Dis Sci. 2021 Nov 20; doi: 10.1007/s10620-021-07299-2. Epub 2021 Nov 20.

BACKGROUND: Hepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in...

Cite
Dong TS, Jacobs JP, Agopian V, et al. Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis. Dig Dis Sci. 2021;doi: 10.1007/s10620-021-07299-2.
Dong, T. S., Jacobs, J. P., Agopian, V., Pisegna, J. R., Ayoub, W., Durazo, F., Enayati, P., Sundaram, V., Benhammou, J. N., Noureddin, M., Choi, G., Lagishetty, V., Fiehn, O., Goodman, M. T., Elashoff, D., & Hussain, S. K. (2021). Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis. Digestive diseases and sciences, . https://doi.org/10.1007/s10620-021-07299-2
Dong, Tien S, et al. "Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis." Digestive diseases and sciences vol. (2021). doi: https://doi.org/10.1007/s10620-021-07299-2
Dong TS, Jacobs JP, Agopian V, Pisegna JR, Ayoub W, Durazo F, Enayati P, Sundaram V, Benhammou JN, Noureddin M, Choi G, Lagishetty V, Fiehn O, Goodman MT, Elashoff D, Hussain SK. Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis. Dig Dis Sci. 2021 Nov 20; doi: 10.1007/s10620-021-07299-2. Epub 2021 Nov 20. PMID: 34799768.
Copy Download .nbib Format: NLM
Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers.

Cancers

Neal A, Lai T, Singh T, Rahseparian N, Grogan T, Elashoff D, Scott P, Pellegrini M, Memarzadeh S.
PMID: 34885017
Cancers (Basel). 2021 Nov 24;13(23). doi: 10.3390/cancers13235908.

Ovarian malignancies are a leading cause of cancer-related death for US women. High-grade serous ovarian carcinomas (HGSOCs), the most common ovarian cancer subtype, are aggressive tumors with poor outcomes. Mutations in TP53 are common in HGSOCs, with a subset...

Cite
Neal A, Lai T, Singh T, et al. Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13235908.
Neal, A., Lai, T., Singh, T., Rahseparian, N., Grogan, T., Elashoff, D., Scott, P., Pellegrini, M., & Memarzadeh, S. (2021). Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. Cancers, 13(23), . https://doi.org/10.3390/cancers13235908
Neal, Adam, et al. "Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13235908
Neal A, Lai T, Singh T, Rahseparian N, Grogan T, Elashoff D, Scott P, Pellegrini M, Memarzadeh S. Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. Cancers (Basel). 2021 Nov 24;13(23). doi: 10.3390/cancers13235908. PMID: 34885017.
Copy Download .nbib Format: NLM
Quantitative Proteomics Using Formalin-fixed, Paraffin-embedded Biopsy Tissues in Inflammatory Disease.

Journal of proteomics & bioinformatics

Amarnani A, Capri JR, Souda P, Elashoff DA, Lopez IA, Whitelegge JP, Singh RR.
PMID: 32431480
J Proteomics Bioinform. 2019;12(7):104-112. doi: 10.35248/0974-276X.12.19.503. Epub 2019 Oct 03.

BACKGROUND: Investigations in human disease pathogenesis have been hampered due to paucity of access to fresh-frozen tissues (FFT) for use in global, data-driven methodologies. As an alternative, formalin-fixed, paraffin-embedded (FFPE) tissues are readily available in pathology banks. However, the...

Cite
Amarnani A, Capri JR, Souda P, et al. Quantitative Proteomics Using Formalin-fixed, Paraffin-embedded Biopsy Tissues in Inflammatory Disease. J Proteomics Bioinform. 2019;12(7):104-112doi: 10.35248/0974-276X.12.19.503.
Amarnani, A., Capri, J. R., Souda, P., Elashoff, D. A., Lopez, I. A., Whitelegge, J. P., & Singh, R. R. (2019). Quantitative Proteomics Using Formalin-fixed, Paraffin-embedded Biopsy Tissues in Inflammatory Disease. Journal of proteomics & bioinformatics, 12(7), 104-112. https://doi.org/10.35248/0974-276X.12.19.503
Amarnani, Abhimanyu, et al. "Quantitative Proteomics Using Formalin-fixed, Paraffin-embedded Biopsy Tissues in Inflammatory Disease." Journal of proteomics & bioinformatics vol. 12,7 (2019): 104-112. doi: https://doi.org/10.35248/0974-276X.12.19.503
Amarnani A, Capri JR, Souda P, Elashoff DA, Lopez IA, Whitelegge JP, Singh RR. Quantitative Proteomics Using Formalin-fixed, Paraffin-embedded Biopsy Tissues in Inflammatory Disease. J Proteomics Bioinform. 2019;12(7):104-112. doi: 10.35248/0974-276X.12.19.503. Epub 2019 Oct 03. PMID: 32431480; PMCID: PMC7236785.
Copy Download .nbib Format: NLM
Abnormal Paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies.

Rheumatology (Oxford, England)

Bae SS, Shahbazian A, Wang J, Golub I, Oganesian B, Dowd T, Vayngortin B, Wang R, Elashoff D, Reddy ST, Charles-Schoeman C.
PMID: 34698804
Rheumatology (Oxford). 2021 Oct 26; doi: 10.1093/rheumatology/keab795. Epub 2021 Oct 26.

OBJECTIVES: Patients with idiopathic inflammatory myopathies (IIM) have severe vascular involvement, which contributes to disease morbidity and mortality. Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL) associated protein, which protects the vascular endothelium from oxidative injury and damage. The current...

Cite
Bae SS, Shahbazian A, Wang J, et al. Abnormal Paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab795.
Bae, S. S., Shahbazian, A., Wang, J., Golub, I., Oganesian, B., Dowd, T., Vayngortin, B., Wang, R., Elashoff, D., Reddy, S. T., & Charles-Schoeman, C. (2021). Abnormal Paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab795
Bae, Sangmee Sharon, et al. "Abnormal Paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab795
Bae SS, Shahbazian A, Wang J, Golub I, Oganesian B, Dowd T, Vayngortin B, Wang R, Elashoff D, Reddy ST, Charles-Schoeman C. Abnormal Paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2021 Oct 26; doi: 10.1093/rheumatology/keab795. Epub 2021 Oct 26. PMID: 34698804.
Copy Download .nbib Format: NLM
Correction: Electronic Video Consent to Power Precision Health Research: A Pilot Cohort Study.

JMIR formative research

Naeim A, Dry S, Elashoff D, Xie Z, Petruse A, Magyar C, Johansen L, Werre G, Lajonchere C, Wenger N.
PMID: 34673529
JMIR Form Res. 2021 Oct 21;5(10):e33891. doi: 10.2196/33891.

[This corrects the article DOI: 10.2196/29123.].

Cite
Naeim A, Dry S, Elashoff D, et al. Correction: Electronic Video Consent to Power Precision Health Research: A Pilot Cohort Study. JMIR Form Res. 2021;5(10):e33891doi: 10.2196/33891.
Naeim, A., Dry, S., Elashoff, D., Xie, Z., Petruse, A., Magyar, C., Johansen, L., Werre, G., Lajonchere, C., & Wenger, N. (2021). Correction: Electronic Video Consent to Power Precision Health Research: A Pilot Cohort Study. JMIR formative research, 5(10), e33891. https://doi.org/10.2196/33891
Naeim, Arash, et al. "Correction: Electronic Video Consent to Power Precision Health Research: A Pilot Cohort Study." JMIR formative research vol. 5,10 (2021): e33891. doi: https://doi.org/10.2196/33891
Naeim A, Dry S, Elashoff D, Xie Z, Petruse A, Magyar C, Johansen L, Werre G, Lajonchere C, Wenger N. Correction: Electronic Video Consent to Power Precision Health Research: A Pilot Cohort Study. JMIR Form Res. 2021 Oct 21;5(10):e33891. doi: 10.2196/33891. PMID: 34673529; PMCID: PMC8569543.
Copy Download .nbib Format: NLM
Protocol for pragmatic randomised trial: integrating electronic health record-based behavioural economic 'nudges' into the electronic health record to reduce preoperative testing for patients undergoing cataract surgery.

BMJ open

Ahmadi A, Sorensen A, Villaflores CWA, Mafi JN, Vangala SS, Hofer IS, Bartlett JD, Cheng EM, Duval VF, Damberg C, Elashoff D, Goldstein NJ, Ladapo JA, Moore JM, Pessegueiro AM, Shu SB, Skootsky SA, Turner A, Sarkisian CA.
PMID: 34732478
BMJ Open. 2021 Nov 03;11(11):e049568. doi: 10.1136/bmjopen-2021-049568.

INTRODUCTION: Robust randomised trial data have shown that routine preoperative (pre-op) testing for cataract surgery patients is inappropriate. While guidelines have discouraged testing since 2002, cataract pre-op testing rates have remained unchanged since the 1990s. Given the challenges of...

Cite
Ahmadi A, Sorensen A, Villaflores CWA, et al. Protocol for pragmatic randomised trial: integrating electronic health record-based behavioural economic 'nudges' into the electronic health record to reduce preoperative testing for patients undergoing cataract surgery. BMJ Open. 2021;11(11):e049568doi: 10.1136/bmjopen-2021-049568.
Ahmadi, A., Sorensen, A., Villaflores, C. W. A., Mafi, J. N., Vangala, S. S., Hofer, I. S., Bartlett, J. D., Cheng, E. M., Duval, V. F., Damberg, C., Elashoff, D., Goldstein, N. J., Ladapo, J. A., Moore, J. M., Pessegueiro, A. M., Shu, S. B., Skootsky, S. A., Turner, A., & Sarkisian, C. A. (2021). Protocol for pragmatic randomised trial: integrating electronic health record-based behavioural economic 'nudges' into the electronic health record to reduce preoperative testing for patients undergoing cataract surgery. BMJ open, 11(11), e049568. https://doi.org/10.1136/bmjopen-2021-049568
Ahmadi, Alast, et al. "Protocol for pragmatic randomised trial: integrating electronic health record-based behavioural economic 'nudges' into the electronic health record to reduce preoperative testing for patients undergoing cataract surgery." BMJ open vol. 11,11 (2021): e049568. doi: https://doi.org/10.1136/bmjopen-2021-049568
Ahmadi A, Sorensen A, Villaflores CWA, Mafi JN, Vangala SS, Hofer IS, Bartlett JD, Cheng EM, Duval VF, Damberg C, Elashoff D, Goldstein NJ, Ladapo JA, Moore JM, Pessegueiro AM, Shu SB, Skootsky SA, Turner A, Sarkisian CA. Protocol for pragmatic randomised trial: integrating electronic health record-based behavioural economic 'nudges' into the electronic health record to reduce preoperative testing for patients undergoing cataract surgery. BMJ Open. 2021 Nov 03;11(11):e049568. doi: 10.1136/bmjopen-2021-049568. PMID: 34732478; PMCID: PMC8572383.
Copy Download .nbib Format: NLM
Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis.

BMC rheumatology

Razmjou AA, Brook J, Elashoff D, Kaeley G, Choi S, Kermani T, Ranganath VK.
PMID: 33089069
BMC Rheumatol. 2020 Oct 19;4:55. doi: 10.1186/s41927-020-00153-4. eCollection 2020.

BACKGROUND: Musculoskeletal ultrasound (MSUS) and the multi-biomarker disease activity (MBDA) score are outcome measures that may aid in the management of rheumatoid arthritis (RA) patients. This study evaluated tofacitinib response by MSUS/MBDA scores and assessed whether baseline MSUS/MBDA scores...

Cite
Razmjou AA, Brook J, Elashoff D, et al. Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis. BMC Rheumatol. 2020;4:55doi: 10.1186/s41927-020-00153-4.
Razmjou, A. A., Brook, J., Elashoff, D., Kaeley, G., Choi, S., Kermani, T., & Ranganath, V. K. (2020). Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis. BMC rheumatology, 455. https://doi.org/10.1186/s41927-020-00153-4
Razmjou, Amir A, et al. "Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis." BMC rheumatology vol. 4 (2020): 55. doi: https://doi.org/10.1186/s41927-020-00153-4
Razmjou AA, Brook J, Elashoff D, Kaeley G, Choi S, Kermani T, Ranganath VK. Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis. BMC Rheumatol. 2020 Oct 19;4:55. doi: 10.1186/s41927-020-00153-4. eCollection 2020. PMID: 33089069; PMCID: PMC7569763.
Copy Download .nbib Format: NLM
An Integrated, Scalable, Electronic Video Consent Process to Power Precision Health Research: Large, Population-Based, Cohort Implementation and Scalability Study.

Journal of medical Internet research

Lajonchere C, Naeim A, Dry S, Wenger N, Elashoff D, Vangala S, Petruse A, Ariannejad M, Magyar C, Johansen L, Werre G, Kroloff M, Geschwind D.
PMID: 34889741
J Med Internet Res. 2021 Dec 08;23(12):e31121. doi: 10.2196/31121.

BACKGROUND: Obtaining explicit consent from patients to use their remnant biological samples and deidentified clinical data for research is essential for advancing precision medicine.OBJECTIVE: We aimed to describe the operational implementation and scalability of an electronic universal consent process...

Cite
Lajonchere C, Naeim A, Dry S, et al. An Integrated, Scalable, Electronic Video Consent Process to Power Precision Health Research: Large, Population-Based, Cohort Implementation and Scalability Study. J Med Internet Res. 2021;23(12):e31121doi: 10.2196/31121.
Lajonchere, C., Naeim, A., Dry, S., Wenger, N., Elashoff, D., Vangala, S., Petruse, A., Ariannejad, M., Magyar, C., Johansen, L., Werre, G., Kroloff, M., & Geschwind, D. (2021). An Integrated, Scalable, Electronic Video Consent Process to Power Precision Health Research: Large, Population-Based, Cohort Implementation and Scalability Study. Journal of medical Internet research, 23(12), e31121. https://doi.org/10.2196/31121
Lajonchere, Clara, et al. "An Integrated, Scalable, Electronic Video Consent Process to Power Precision Health Research: Large, Population-Based, Cohort Implementation and Scalability Study." Journal of medical Internet research vol. 23,12 (2021): e31121. doi: https://doi.org/10.2196/31121
Lajonchere C, Naeim A, Dry S, Wenger N, Elashoff D, Vangala S, Petruse A, Ariannejad M, Magyar C, Johansen L, Werre G, Kroloff M, Geschwind D. An Integrated, Scalable, Electronic Video Consent Process to Power Precision Health Research: Large, Population-Based, Cohort Implementation and Scalability Study. J Med Internet Res. 2021 Dec 08;23(12):e31121. doi: 10.2196/31121. PMID: 34889741.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 96 entries